BioLight Life Sciences Ltd.

As of June 30, 2022, BioLight Life Sciences Ltd. carries a market capitalization of 4.24B, placing it among publicly traded companies globally. Its enterprise value stands at 1.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2022, BioLight Life Sciences Ltd. has 4.56M shares outstanding.

These figures are as of June 30, 2022.

As of June 30, 2022, BioLight Life Sciences Ltd. maintains a current ratio of 15.69, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2022.

Over the twelve months ended June 30, 2022, BioLight Life Sciences Ltd. recorded an income tax benefit of -131.30M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, BioLight Life Sciences Ltd.'s stock has declined approximately 26.77% over the past 52 weeks. The 50-day moving average sits at 305.88, while the 200-day moving average is 326.88.

As of June 30, 2022, BioLight Life Sciences Ltd. holds 2.54B in cash and equivalents against 21.10M in total debt, resulting in a net debt position of -785.30M. Total book value stands at 6.32B, with working capital of 2.43B providing operational flexibility.

BioLight Life Sciences Ltd.'s most recent stock split took place on April 24, 2018.